Balancing Affordability and Need: Should We Use Renal Denervation in Hypertension Management?

Overview

Journal J Soc Cardiovasc Angiogr Interv

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 11

PMID 39525999

Authors

Lucas Lauder

Thilo Burkard

Felix Mahfoud

Affiliations

Soon will be listed here.

References

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

Kirkland E, Heincelman M, Bishu K, Schumann S, Schreiner A, Axon R . Trends in Healthcare Expenditures Among US Adults With Hypertension: National Estimates, 2003-2014. J Am Heart Assoc. 2018; 7(11). PMC: 6015342. DOI: 10.1161/JAHA.118.008731. View

Egan B, Li J, Sutherland S, Rakotz M, Wozniak G . Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups. Hypertension. 2021; 78(3):578-587. DOI: 10.1161/HYPERTENSIONAHA.120.16418. View

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A . 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal.... J Hypertens. 2023; 41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. View

Sharp A, Cao K, Esler M, Kandzari D, Lobo M, Schmieder R . Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes. 2024; 10(8):698-708. PMC: 11656065. DOI: 10.1093/ehjqcco/qcae001. View

Sharp A, Tunev S, Schlaich M, Lee D, Finn A, Trudel J . Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. J Hypertens. 2022; 40(10):2068-2075. PMC: 9451943. DOI: 10.1097/HJH.0000000000003236. View

Al Ghorani H, Kulenthiran S, Lauder L, Recktenwald M, Dederer J, Kunz M . Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes. Clin Res Cardiol. 2024; 113(10):1384-1392. PMC: 11420252. DOI: 10.1007/s00392-024-02417-2. View

Moser M . Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich). 2006; 8(8 Suppl 2):15-20. PMC: 8109518. DOI: 10.1111/j.1524-6175.2006.05836.x. View

10.

Thomopoulos C, Parati G, Zanchetti A . Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014; 32(12):2285-95. DOI: 10.1097/HJH.0000000000000378. View

11.

Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J . Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022; 18(8):e677-e685. PMC: 10241283. DOI: 10.4244/EIJ-D-22-00305. View

12.

Lauder L, Kandzari D, Luscher T, Mahfoud F . Renal denervation in the management of hypertension. EuroIntervention. 2024; 20(8):e467-e478. PMC: 11017226. DOI: 10.4244/EIJ-D-23-00836. View

13.

Whelton P, Carey R, Aronow W, Casey Jr D, Collins K, Himmelfarb C . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association.... Hypertension. 2017; 71(6):1269-1324. DOI: 10.1161/HYP.0000000000000066. View

14.

Mahfoud F, Kandzari D, Kario K, Townsend R, Weber M, Schmieder R . Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022; 399(10333):1401-1410. DOI: 10.1016/S0140-6736(22)00455-X. View

15.

Charchar F, Prestes P, Mills C, Ching S, Neupane D, Marques F . Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2023; 42(1):23-49. PMC: 10713007. DOI: 10.1097/HJH.0000000000003563. View

16.

Lauder L, Mahfoud F, Azizi M, Bhatt D, Ewen S, Kario K . Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2022; 44(23):2066-2077. DOI: 10.1093/eurheartj/ehac395. View

17.

Mahfoud F, Mancia G, Schmieder R, Ruilope L, Narkiewicz K, Schlaich M . Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range. J Am Coll Cardiol. 2022; 80(20):1871-1880. DOI: 10.1016/j.jacc.2022.08.802. View

18.

. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967; 202(11):1028-34. View

19.

Kandzari D, Townsend R, Kario K, Mahfoud F, Weber M, Schmieder R . Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023; 82(19):1809-1823. DOI: 10.1016/j.jacc.2023.08.045. View

20.

Magnussen C, Ojeda F, Leong D, Alegre-Diaz J, Amouyel P, Aviles-Santa L . Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023; 389(14):1273-1285. PMC: 10589462. DOI: 10.1056/NEJMoa2206916. View